SOP for Preparation of Method Development Protocol in Analytical R&D
Department | Analytical Method Development |
---|---|
SOP No. | SOP/AMD/013/2025 |
Supersedes | SOP/AMD/013/2022 |
Page No. | Page 1 of 14 |
Issue Date | 19/05/2025 |
Effective Date | 20/05/2025 |
Review Date | 19/05/2026 |
1. Purpose
The purpose of this SOP is to define the procedure for the preparation, review, approval, and archival of the Method Development Protocol (MDP). The protocol provides a pre-defined framework for conducting method development studies
in compliance with ICH Q2(R1), Q8, WHO TRS, and GMP requirements.
2. Scope
This SOP applies to all method development activities carried out for active pharmaceutical ingredients (APIs), finished dosage forms, excipients, and raw materials in the Analytical Method Development (AMD) department.
3. Responsibilities
- Analytical Scientist: Drafts the method development protocol with technical input and planned experimentation details.
- Team Leader: Reviews the draft protocol for scientific soundness and compliance with project objectives.
- QA: Ensures the protocol includes all mandatory sections and is documented as per QMS guidelines.
- Head – AMD: Approves the final protocol prior to initiation of development studies.
4. Accountability
The Head of Analytical Method Development is accountable for ensuring that all method development activities are initiated only after an approved Method Development Protocol is in place and followed.
5. Procedure
5.1 Protocol Initiation
- Initiate the protocol upon receipt of a new method development request (analytical R&D form or project kickoff).
- Assign protocol number as per the defined format: MDP/YY/XXX (where YY = year, XXX = serial number).
5.2 Protocol Structure
- Prepare the Method Development Protocol using the template outlined in Annexure-1.
- The protocol must include the following sections:
- Objective
- Scope
- Product and Analyte Information
- Analytical Target Profile (ATP)
- Materials and Instruments
- Proposed Analytical Technique(s)
- Development Strategy
- Acceptance Criteria
- Documentation and Reporting
- Risk Assessment (if applicable)
5.3 Drafting the Protocol
- Input detailed product information, chemical structure, solubility, pKa, degradation pathways, and known impurities.
- Define critical method parameters and their expected impact on performance (CMPs).
- Include literature summary and justification for method selection or deviation from pharmacopoeial method.
- Record drafting details in Annexure-2: Protocol Drafting Log.
5.4 Review and Approval
- Submit draft protocol to Team Lead and QA for review.
- Incorporate feedback and corrections.
- Finalize and route for approval by Head – AMD and QA signatories.
- Attach approval sheet as Annexure-3.
5.5 Protocol Implementation
- Initiate method development activities only after the protocol has been formally approved and recorded in the protocol tracker log.
- Ensure that all activities, observations, trials, and deviations are recorded in the Method Development Workbook or ELN.
- Cross-reference Method Development Protocol in Method Development Report.
5.6 Documentation and Archival
- Maintain soft and hard copies of the approved protocol under document control.
- Attach protocol to method development dossier and archive as per QMS.
- Record protocol status in Annexure-4: Protocol Tracking Sheet.
6. Abbreviations
- MDP: Method Development Protocol
- ATP: Analytical Target Profile
- CMP: Critical Method Parameter
- QA: Quality Assurance
- AMD: Analytical Method Development
- QMS: Quality Management System
- ELN: Electronic Lab Notebook
7. Documents
- Method Development Protocol Template – Annexure-1
- Protocol Drafting Log – Annexure-2
- Protocol Approval Sheet – Annexure-3
- Protocol Tracking Sheet – Annexure-4
8. References
- ICH Q2(R1) – Validation of Analytical Procedures
- ICH Q8 – Pharmaceutical Development
- ICH Q9 – Quality Risk Management
- WHO TRS 996 – Annex 3
9. SOP Version
Version: 2.0
10. Approval Section
Prepared By | Checked By | Approved By | |
---|---|---|---|
Signature | |||
Date | |||
Name | |||
Designation | |||
Department |
11. Annexures
Annexure-1: Method Development Protocol Template
Section | Description |
---|---|
Objective | To develop an HPLC method for API assay and related substances |
Technique | Reverse-Phase HPLC with UV detection |
Strategy | Initial scouting, followed by optimization and forced degradation confirmation |
Annexure-2: Protocol Drafting Log
Date | Drafted By | Reviewed By | Version |
---|---|---|---|
10/05/2025 | Sunita Reddy | Rajesh Kumar | V1.0 |
Annexure-3: Protocol Approval Sheet
Role | Name | Signature | Date |
---|---|---|---|
Prepared By | |||
Checked By | |||
Approved By |
Annexure-4: Protocol Tracking Sheet
Protocol No. | Product | Initiation Date | Status | Archived |
---|---|---|---|---|
MDP/25/007 | Metformin Tablets | 12/05/2025 | Approved | Yes |
Revision History:
Revision Date | Revision No. | Details | Reason | Approved By |
---|---|---|---|---|
04/05/2025 | 2.0 | Expanded structure and added protocol tracking annexure | Audit compliance |